Aug 27 2009
Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) and its majority owned subsidiary Entest BioMedical Inc. (OTCBB: ENTB) announced today they have finalized a definitive agreement with Therinject LLC for the development of a new immuno-therapeutic cancer vaccine. Therinject LLC is engaged in the development of cancer treatments utilizing immunology based approaches.
It is anticipated that BMSN’s facilities and infrastructure will be utilized by both parties for the development of immuno-therapeutic treatments for cancer. Initially, BMSN and Therinject intend to focus on the veterinary market, looking to treat animals with tumors while gathering data in support of human clinical trials.
Bio-Matrix Chairman & CEO David Koos stated, “Cancer is the #1 cause of death among dogs. It’s estimated that 1 out of every 3 dogs will get cancer. We anticipate this immuno-therapeutic cancer vaccine could have an efficacy rate of as high as 60% where 15% to 20% is the current cure rate. We believe that during the first year this immuno-therapeutic vaccine is available we will treat roughly 2,000 animals resulting in $3,000 revenue per animal or $6 million in first year revenue from veterinary medical applications. The Company anticipates a market niche over the subsequent 5 years of 40,000 animals being treated. This is before we expand to human clinical trials.”
Therinject’s Chief Scientific Officer, Steven Josephs, Ph.D. said that, “For many cancers, efficacy rates should be much higher than currently available therapies. Immuno-therapy stimulates the body’s own immune system to engage in the treatment process. The development of an anti-cancer immune response would be very effective in dealing with metastatic tumors especially in cases where surgery would no longer be feasible.”
Additionally, Therinject will work with Entest BioMedical’s team to develop intellectual property in this area of cancer treatment , which is anticipated to result in patents being applied for by Entest BioMedical Inc. (OTCBB: ENTB), a majority owned subsidiary of BMSN.
Entest believes the technology to be developed has potential for uses beyond the initial applications.
New nasal vaccine could help stop the spread of whooping cough